08:28 AM EDT, 07/29/2024 (MT Newswires) -- HLS Therapeutics ( HLTRF ) , which gained more than 6% from near 52 week lows last Friday, on Monday entered into a Product Listing Agreement (PLA) with the province of Alberta, for the listing and public reimbursement of Vascepa (icosapent ethyl).

A statement noted the PLA is effective August 1. The product will be reimbursed by Alberta Health for the secondary prevention of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides.

"The PLA with Alberta Health will significantly improve access and reimbursement for Vascepa in Canada's fourth largest province," said Craig Millian, CEO of HLS.

The statement notes that with the addition of Alberta's public plan, Vascepa will be available to more than 90% of Canadians who are eligible and covered by a public or private plan.